Buyout buzz: Sanofi, J&J and Abbott in the hunt for Bausch + Lomb

The crew at Bloomberg has ferreted details from a process to sell privately owned drug and device company Bausch + Lomb, with giants Abbott Laboratories ($ABT), Johnson & Johnson ($JNJ) and Sanofi ($SNY) reportedly in the chase to acquire the company, unnamed sources told the news service. Private equity owner Warburg Pincus might be seeking $10 billion or more for Bausch + Lomb, asking 12 to 13 times more than the business is projected to rake in during 2013. Article | More



Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.